LTRN

Lantern Pharma Inc

Add to Watchlist

Advanced Chart

4.010

+0.14(3.618%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.090

Open

4.000

VWAP

3.95

Vol

78.66K

Mkt Cap

43.25M

Low

3.830

Amount

310.33K

EV/EBITDA(TTM)

Total Shares

10.76M

23.53M

EV/OCF(TTM)

P/S(TTM)

Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

1 Analyst Rating

523.44% Upside

Wall Street analysts forecast LTRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LTRN is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

523.44% Upside

Current: 4.010

Low

25.00

Averages

25.00

High

25.00

523.44% Upside

Current: 4.010

Low

25.00

Averages

25.00

High

25.00

Lake Street

Chad Messer

Strong Buy

Initiates

$25

2025-04-02

Reason

Lake Street

Chad Messer

Price Target

$25

2025-04-02

Initiates

Strong Buy

Reason

Lake Street initiated coverage of Lantern Pharma with a Buy rating and $25 price target. Lantern's Response Algorithm for Drug Positioning and Rescue, or RADR, platform consists of a suite of AI modules designed to help advance cancer drug development, the analyst tells investors. Unlike many biotech AI platform companies, Lantern is monetizing RADR through advancement of its own pipeline of four clinical, plus additional preclinical, stage molecules, though they also engage in collaborations with partners, adds the analyst, who notes that lead clinical program LP-300 targets a unique set of lung cancer patients who never smoked.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Lantern Pharma Inc (LTRN.O) is -2.20, compared to its 5-year average forward P/E of -5.16. For a more detailed relative valuation and DCF analysis to assess Lantern Pharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.16

Current PE

-2.20

Overvalued PE

-0.68

Undervalued PE

-9.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.73

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.51

Undervalued EV/EBITDA

-2.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00